Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3065 participants.
Also called NCT03037931
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,065 participants
- Registry
-
NCT03037931
-
- Other papers using this trial's data
- Ferric Carboxymaltose in Heart Failure with Iron Deficiency
- Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Bulgaria, Canada, Czechia, Georgia, Hungary, Latvia, Lithuania, New Zealand, Poland, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03037931. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
- Acronym
- HEART-FID
- Condition
- Heart Failure
- Condition
- Iron-deficiency
- Intervention (Drug)
- Ferric Carboxymaltose
- Intervention (Drug)
- Placebo
- Lead sponsor
- American Regent, Inc.
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct03037931- Content hash
e92a9ca90af31f0550c2032d38f0d2424ce7b8b7411b775330a31feec4d379ef